<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03182374</url>
  </required_header>
  <id_info>
    <org_study_id>APSS-66-00</org_study_id>
    <nct_id>NCT03182374</nct_id>
  </id_info>
  <brief_title>nSTRIDE APS Versus Hyaluronic Acid for Knee Osteoarthritis</brief_title>
  <official_title>A Two-Phase, Multicenter, Randomized Study Comparing Autologous Protein Solution With Hyaluronic Acid Intra Articular Injections in Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-phase multicenter, double-blind, randomized, prospective evaluation of
      intra-articular injection(s) comparing APS to intra-articular HA injection(s). The maximum
      study duration for each subject will be 62 months; 60 months from treatment to last
      follow-up, and two additional months if the maximum visit window is realized. A total of 246
      patients will be enrolled. These patients will meet specific inclusion and exclusion
      criteria, but can be generally characterized as patients with painful unilateral knee OA who
      have been unable to achieve satisfactory pain relief with previous conservative OA treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 14, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>During the long-term follow-up phase (12 - 60 months), subjects may also elect to cross over to the other treatment arm and receive additional injections of the other treatment as frequently as needed, provided they did not experience any significant clinical concerns after previous treatment administrations and are benefiting from it, as determined by the investigator. Subjects may only cross over from their originally assigned treatment group to the other treatment group one time during the study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is a double-blind study where subjects and evaluators are blinded to treatment up to 12-months. During the long-term follow-up phase (12 - 60 months), only subjects will be blinded to the study treatment resulting in single-blind design following 12-month follow-up time point.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Comparing Autologous Protein Solution (APS) with Hyaluronic Acid (HA) Intra Articular Injections</measure>
    <time_frame>12 months</time_frame>
    <description>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) LK 3.1 pain score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NRS pain scale</measure>
    <time_frame>12 months</time_frame>
    <description>Change in pain as measured by NRS pain scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMERACT-OARSI</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of subjects achieving clinical success as defined by OMERACT-OARSI Responder Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC LK 3.1</measure>
    <time_frame>12 months</time_frame>
    <description>Change in WOMAC LK 3.1 function, stiffness subscale and overall scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>12 months</time_frame>
    <description>Change in quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of AEs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">246</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>nSTRIDE APS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The nSTRIDE APS Kit is designed to be used for the safe and rapid preparation of APS from a small sample of blood at the patient's point of care. The APS is to be injected intra-articularly for the treatment of knee osteoarthritis and associated symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synvisc-One</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Synvisc-One is only intended for intra-articular use by a physician to treat pain associated with osteoarthritis of the knee</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nSTRIDE APS</intervention_name>
    <description>Intra-articular injection</description>
    <arm_group_label>nSTRIDE APS</arm_group_label>
    <other_name>Autologous Protein Solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Synvisc-One</intervention_name>
    <description>Intra-articular injection</description>
    <arm_group_label>Synvisc-One</arm_group_label>
    <other_name>hylan G-F 20</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female at least 18 years of age at time of screening.

          -  Willingness and ability to comply with study procedures and visit schedules and able
             to follow oral and written instructions.

          -  A standing knee radiograph showing a K-L grade of 2 to 4

          -  Body mass index ≤ 40 kg/m2

          -  A qualifying WOMAC LK 3.1 pain subscale total score

          -  Signed an ethics committee-reviewed and approved informed consent form.

        Exclusion Criteria:

          -  Presence of clinically observed active infection in the index knee

          -  Presence of symptomatic OA in the non-study knee at screening

          -  Diagnosed with rheumatoid arthritis, Reiter's syndrome, psoriatic arthritis, gout,
             ankylosing spondylitis, or arthritis secondary to other inflammatory diseases; HIV,
             viral hepatitis; chondrocalcinosis, Paget's disease, or villonodular synovitis

          -  Diagnosed with leukemia, known presence of metastatic malignant cells, or ongoing or
             planned chemotherapeutic treatment

          -  Presence of venous or lymphatic stasis in the index leg

          -  A history of local anesthetic allergy

          -  Previously documented failed treatment with nSTRIDE APS or Synvisc One
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizaveta Kon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanitas University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Monica</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Parker Institute, Frederiksberg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxiskliniek für Unfallchirurgie und Orthopädie</name>
      <address>
        <city>Eisenach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KniePraxis</name>
      <address>
        <city>Straubing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rizzoli Orthopedic Institute</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Istituto Clinico Humanitas</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC+</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital - Olympiatoppen</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yildirim Beyazit University, School of Medicine</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cheltenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh - NHS Lothian</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2017</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autologous Protein Solution (APS)</keyword>
  <keyword>Intra-articular Injection</keyword>
  <keyword>Osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hylan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

